Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Charles Craddock on the latest UK AML trials

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, is taking over the National Cancer Research Institute (NCRI) acute myeloid leukemia (AML) Working Group. Here, he gives us an update on the latest UK AML trial strategy, including molecular profiling, measurable residual disease detection, and the IMPACT trials transplant clinical trials partnership that is launcing two trials currently: COSI and AMADEUS. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.